ZHX2 and nonpapillary renal cell carcinoma: Pharmacological inhibition of Hippo/MST1/2 kinase activity inhibited p65/ZHX2 cooperativity, leading to diminished NF-κB target gene expression and inhibited ccRCC tumor growth, which can be alleviated by increasing the activity of ZHX2 or p65.